Insiders seem to have made the most of their holdings by selling US$684k worth of Sagimet Biosciences Inc. (NASDAQ:SGMT) stock at an average sell price of US$7.26 during the past year. The company's market valuation decreased by US$106m after the stock price dropped 14% over the past week, but insiders were spared from painful losses.
While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.
In the last twelve months, the biggest single sale by an insider was when the CEO, President & Director, David Happel, sold US$497k worth of shares at a price of US$7.76 per share. That means that an insider was selling shares at slightly below the current price (US$9.85). We generally consider it a negative if insiders have been selling, especially if they did so below the current price, because it implies that they considered a lower price to be reasonable. While insider selling is not a positive sign, we can't be sure if it does mean insiders think the shares are fully valued, so it's only a weak sign. It is worth noting that this sale was only 15% of David Happel's holding.
Sagimet Biosciences insiders didn't buy any shares over the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!
Check out our latest analysis for Sagimet Biosciences
For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket.
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Our data indicates that Sagimet Biosciences insiders own about US$6.7m worth of shares (which is 1.0% of the company). We do generally prefer see higher levels of insider ownership.
It doesn't really mean much that no insider has traded Sagimet Biosciences shares in the last quarter. Our analysis of Sagimet Biosciences insider transactions leaves us unenthusiastic. We also note that, as far as we can see, insider ownership is fairly low, compared to other companies. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. When we did our research, we found 4 warning signs for Sagimet Biosciences (2 don't sit too well with us!) that we believe deserve your full attention.
But note: Sagimet Biosciences may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.